3 big takeaways from SLAS on the future of automation and screening

February 11, 2020 NanoTemper Technologies

NanoTemper at SLAS conference

5,200 researchers, representing all of life sciences, gathered in San Diego in late January to discuss the latest in automation and screening solutions. Improvements in automation and screening are a win for all researchers, helping them get to precise answers more quickly and cost-effectively. This year, there was a particular focus on advancements in the field of gene therapy.

From all of the exciting new findings, here are the top three takeaways we observed at SLAS 2020.


1. Get to a deeper characterization of lead candidates sooner in the workflow

With continued improvements in automation and screening technologies, researchers are demanding more biophysical analysis of their proteins such as stability, aggregation and binding interactions earlier on in their workflows as they select their lead targets.


2. Define the link between RNA and gene therapy

During the Druggable RNA session, the role of structural RNA was the focus of discussion. Even though ~85% of the human genome is transcribed into RNA, only ~3% encode proteins. This abundance of structural RNAs have functions waiting to be revealed and could be the next emerging class of biotherapeutic targets.


3. Confirm the relevance of your targets in cell-based approaches

With advances made in 3D cultures and on organs-on-a-chip technologies, researchers are gaining a stronger understanding of the interactions involved in diseases such as cancer and neurodegenerative disorders.


Are you ready to learn about the latest in automation and screening to help your research?

Scientists who have struggled with fragment-based drug discovery screening are choosing Dianthus as their solution to quickly and precisely select the hits that are missed by other technologies.

Learn how you can screen for hits faster with Dianthus.


Stay on the journey for the key takeaways from life science conferences. Here is where NanoTemper is heading next. We’ll make sure to share what we learned.

Previous Video
Tackle small molecule drug discovery screening challenges with Dianthus
Tackle small molecule drug discovery screening challenges with Dianthus

A big hurdle in small molecule drug discovery screening is confidently identifying positive hits in a timel...

Up next
Neurodegenerative Diseases: Studying protein aggregation using NanoTemper instruments
Neurodegenerative Diseases: Studying protein aggregation using NanoTemper instruments

Neurodegenerative diseases like Alzheimer’s or Parkinson’s Disease affect millions of people worldwide. Alt...

Have a question about Dianthus?

Contact Specialist

Sign up to receive
the latest NanoTemper news, product updates, event announcements and more

First Name
Last Name
Company Name
Agree to Subscribe & Privacy Policy*
*I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
Thank you!
Error - something went wrong!